Last checked at 2 Sep 2019 07:00
2 September 2019 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or the "Company")
Block Listing Review and Total Voting Rights
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.
Name: | ReNeuron Group plc |
Name of Scheme: | ReNeuron Share Option Schemes |
Period of Return: | From 1 March 2019 to 31 August 2019 |
Balance of unallotted securities under scheme(s) from previous return: | 902,825 Ordinary Shares (of 1p each)
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for): | N/A |
Less: Number of securities issued/allotted under scheme(s) during period |
186,084 |
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 716,741 Ordinary Shares |
Number and class of securities originally admitted and the date of admission: | 20,000 ordinary shares on 13 May 2010 |
Total Voting Rights
At 31 August 2019, the Company had 31,832,270 ordinary shares in issue, each carrying one voting right. As the Company holds no ordinary shares in treasury, the figure of 31,832,270 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
ENDS
ENQUIRIES:
ReNeuron | +44 (0)20 3819 8400 |
Olav Hellebø, Chief Executive Officer | |
Michael Hunt, Chief Financial Officer
| |
Buchanan | +44 (0) 20 7466 5000 |
Mark Court, Sophie Wills, Tilly Abraham
| |
Stifel Nicolaus Europe Limited | +44 (0) 20 7710 7600 |
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
| |
N+1 Singer | +44 (0) 20 7496 3000 |
Aubrey Powell, James Moat, Mia Gardner (Joint Broker) |
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.